Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Genentech Receives First ADC Approval | Contract Pharma

What are you searching for?

Sign in

Genentech Receives First ADC Approval

Kadcyla approved for HER2-positive metastatic breast cancer

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Genentech has received FDA approval for Kadcyla (ado-trastuzumab emtansine or T-DM1) for the treatment of HER2-positive metastatic breast cancer (mBC) in patients that have received prior Herceptin and chemotherapy treatment. Kadcyla, an antibody-drug conjugate (ADC), is a new kind of targeted cancer medicine that can attach to certain types of cancer cells and deliver chemotherapy directly to them. Kadcyla is the first FDA-approved ADC for treating HER2-positive mBC.
 
“Kadcyla is an antibody-drug conjugate representing a completely new way to treat HER2-positive metastatic breast cancer, and it helped people in the EMILIA study live nearly six months longer,” said Hal Barron, M.D., chief medical officer and head, Global Product Development. “We currently have more than 25 ADCs in our pipeline and hope this promising approach will help us deliver more medicines to fight other cancers in the future.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters